An update from KEYNOTE-045 has confirmed the overall survival benefit of pembrolizumab compared to second-line chemotherapy in patients with advanced urothelial cancer. The research, presented at the ESMO 2017 Congress, found overall survival increased from 7.4 months with chemotherapy to 10.3 months with pembrolizumab after more than 22 months of follow-up. The 18-month overall survival ...
Checkpoint inhibition extending life in bladder cancer
By Mardi Chapman
20 Sep 2017